Rob Hess

Angel Investor, Board Member for the Life Science Angels (LSA), Board Observer for NuFund Venture Group.

Rob is an angel investor (>100 angel investments) focusing primarily on Pharma/Biotech, Medtech, and software. He is curently a board member for the Life Science Angels (LSA), board observer for NuFund Venture Group.

Exits include Noctrix Health (Resmed), Atraverse Medical (J&J), DTX Pharma (Novartis), SpineAlign, OnScale, Gravyty, Begin, Octane AI (Moltbook). Some holdings include Promaxo, Neuro42, LabViva, Seal Rock Therapeutics, Vasa Therapeutics, mmTron, Givzey, Overlord Labs, Avisi Technologie, Evress Analytic, Encharge, Sinopia Bio, Allyx Therapeutic, Kueski, Letterhead, Journey and Mebias Discovery.

Rob is a also patent attorney and advises companies in the medtech and biopharma space on matters of patent strategy in order to help them produce high-value patent portfolios. He previously held both in-house and private practice positions as a patent attorney, primarily prosecuting patents in the biotechnology and medical device fields.

Rob holds.a B.S. in Biochemistry from Cornell University, a Ph.D. in Molecular Biophysics from University of Wisconsin - Madison, and a J.D. from Suffolk University Law School.